Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Wierda

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Immunotoxicology|October 30, 2008
Preclinical immunogenicity testing for recombinant therapeutic proteinsHolly W Smith, Daniel Wierda
Toxicology|November 26, 2003
A predictive F344 rat immunotoxicology model: cellular parameters combined with humoral response to NP-CgammaG and KLHHolly W Smith, Colleen J Winstead, Kristen K Stank, et al.
Journal of Immunotoxicology|January 15, 2015
Fully human anti-BAFF inhibitory monoclonal antibody tabalumab does not adversely affect T-dependent antibody responses in cynomolgus monkey (Macaca fasicularis): A summary of three pre-clinical immunotoxicology evaluationsWendy J Komocsar, Jamie L Blackbourne, Carolyn A Halstead, et al.
The Journal of Allergy and Clinical Immunology|March 19, 2002
Task force report: future research needs for the prevention and management of immune-mediated drug hypersensitivity reactionsN Franklin Adkinson, David Essayan, Rebecca Gruchalla, et al.
Journal of Immunotoxicology|March 21, 2012
Developmental immunotoxicity (DIT) testing of pharmaceuticals: current practices, state of the science, knowledge gaps, and recommendationsMark Collinge, Leigh Ann Burns-Naas, Gary J Chellman, et al.
Journal of Immunotoxicology|June 13, 2009
Summary of a workshop on nonclinical and clinical immunotoxicity assessment of immunomodulatory drugsJoseph R Piccotti, Herve N Lebrec, Ellen Evans, et al.
Journal of Immunological Methods|July 15, 2004
Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology productsAnthony R Mire-Sluis, Yu Chen Barrett, Viswanath Devanarayan, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Immunotoxicology|October 30, 2008
Preclinical immunogenicity testing for recombinant therapeutic proteinsHolly W Smith, Daniel Wierda
Toxicology|November 26, 2003
A predictive F344 rat immunotoxicology model: cellular parameters combined with humoral response to NP-CgammaG and KLHHolly W Smith, Colleen J Winstead, Kristen K Stank, et al.
Journal of Immunotoxicology|January 15, 2015
Fully human anti-BAFF inhibitory monoclonal antibody tabalumab does not adversely affect T-dependent antibody responses in cynomolgus monkey (Macaca fasicularis): A summary of three pre-clinical immunotoxicology evaluationsWendy J Komocsar, Jamie L Blackbourne, Carolyn A Halstead, et al.
The Journal of Allergy and Clinical Immunology|March 19, 2002
Task force report: future research needs for the prevention and management of immune-mediated drug hypersensitivity reactionsN Franklin Adkinson, David Essayan, Rebecca Gruchalla, et al.
Journal of Immunotoxicology|March 21, 2012
Developmental immunotoxicity (DIT) testing of pharmaceuticals: current practices, state of the science, knowledge gaps, and recommendationsMark Collinge, Leigh Ann Burns-Naas, Gary J Chellman, et al.
Journal of Immunotoxicology|June 13, 2009
Summary of a workshop on nonclinical and clinical immunotoxicity assessment of immunomodulatory drugsJoseph R Piccotti, Herve N Lebrec, Ellen Evans, et al.
Journal of Immunological Methods|July 15, 2004
Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology productsAnthony R Mire-Sluis, Yu Chen Barrett, Viswanath Devanarayan, et al.
Pageof 1